Femasys (FEMY) investor relations material

Company overview and business model

• Develops innovative fertility and non-surgical permanent birth control solutions for women, focusing on in-office therapeutic and diagnostic products with global regulatory approvals and commercialization in the U.S. and key international markets.

• Product portfolio includes FemaSeed (FDA-cleared infertility treatment), FemVue (diagnostic for fallopian tube assessment), FemCerv (cervical cancer diagnosis), and FemBloc (non-surgical permanent birth control), among others.

• Holds approximately 228 issued patents globally and maintains in-house manufacturing and chemistry capabilities.

• Targets multi-billion dollar global market segments with limited recent innovation, aiming to reduce reliance on pharmaceuticals, implants, and surgery.

• Woman-founded and led, with a focus on expanding access and reducing costs for women worldwide.

Financial performance and metrics

• Raised approximately $30 million in gross proceeds from a private placement in August 2026, before deducting offering expenses.

• Recurring losses from operations, negative cash flows, and net capital deficiency raise substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive proceeds from the sale of shares by selling stockholders; will receive proceeds only from cash exercise of warrants.

• Proceeds from warrant exercises are expected to be used for working capital purposes, with broad discretion over allocation.